- Home
- PCB vs BCYC Comparison
PCB vs BCYC Comparison
Compare PCB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCB | BCYC |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | 288 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.0M | 310.7M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCB | BCYC |
|---|---|---|
| Price | $23.38 | $4.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $25.50 | $13.90 |
| AVG Volume (30 Days) | 17.9K | ★ 357.9K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.28 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $2,899,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $31.65 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $19.28 | $4.24 |
| 52 Week High | $25.15 | $9.36 |
Technical Indicators
Market Signals| Indicator | PCB | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 36.50 |
| Support Level | $21.12 | $4.24 |
| Resistance Level | $24.25 | $5.31 |
| Average True Range (ATR) | 0.50 | 0.22 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 7.85 | 3.20 |
Price Performance
Historical ComparisonAbout PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.